Lancet Haematology Podcasts

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.By The Lancet

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continu…

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.…

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article: https://www.th…

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.By The Lancet

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_gen…

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.By The Lancet

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Read the two trials: Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH) https://www.t…

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania Read the full article: Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE) Continue this conversation on social!…

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in TanzaniaBy The Lancet

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia. Read the full article: Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia Continue this conversation on social! Follow us today at... https://twitter.com/thelancet htt…

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.By The Lancet

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.By The Lancet

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China. Read the Series papers: Cellular therapy in China Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://i…

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries. Read the full Review: Achieving access to haemophilia care in low-income and lower-middle-income countries Continue this conversation on social! Follow us today at... http…

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.By The Lancet

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both. Read the full article: Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Continue this conversation on social! Follow us today at... https:…

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.By The Lancet

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care.By The Lancet

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://inst…

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.By The Lancet

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article: Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN) Continue this conversatio…

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext Continu…

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.By The Lancet

Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people. Read the full article: A comprehensive approach to therapy of haematological malignancies in older patients Continue this conversation on social! Follow us today at... https://twitter.com/thelanc…

Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people.By The Lancet

Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria.By The Lancet

Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltext Continue this conversation on social! Follo…

Dr Zuguo Mei and Dr Gary M Brittenham talk about their work defining physiologically based serum ferritin thresholds for iron deficiency.By The Lancet

Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA) and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia Unive…

Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología. C…

To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care. Continue thi…

To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care.…

Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología.…

A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljourna…

A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation.By The Lancet

Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fullt…

Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era.By The Lancet

Andrea Biondi joins The Lancet Haematology to discuss his work on imatinib as a treatment for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia.By The Lancet

Andrea Biondi joins The Lancet Haematology to discuss his work on imatinib as a treatment for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://l…

Prashant Hiwarkar joins The Lancet Haematology to discuss his new paper, an investigation into whether serial faecal PCR monitoring can predict the risk of adenoviraemia and survival outcomes after HSCT.By The Lancet

Prashant Hiwarkar joins The Lancet Haematology to discuss his new paper, an investigation into whether serial faecal PCR monitoring can predict the risk of adenoviraemia and survival outcomes after HSCT. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.co…

Lead author Gita Thanarajasingam joins The Lancet Haematology to discuss the new Commission on assessment and adverse event reporting in haematological malignancies. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://link…

Lead author Gita Thanarajasingam joins The Lancet Haematology to discuss the new Commission on assessment and adverse event reporting in haematological malignancies.By The Lancet

Jules Heuberger talks about his study on the effectiveness of EPO use by cyclists. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv…

Jules Heuberger talks about his study on the effectiveness of EPO use by cyclists.By The Lancet

Petra Innerhofer discusses reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lance…

Petra Innerhofer discusses reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma.By The Lancet

Audrey Bonaventure discusses her CONCORD-2 study, monitoring survival trends of two types of childhood leukaemia in 53 countries between 1995 and 2009. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/compa…

Audrey Bonaventure discusses her CONCORD-2 study, monitoring survival trends of two types of childhood leukaemia in 53 countries between 1995 and 2009.By The Lancet